TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. active macula-involved polypoidal lesions evidenced by ICGA;~2. greatest linear dimension of 5400 μm or less assessed by ICGA;~3. follow-up of at least 12 months.~Exclusion Criteria:~1. any other ocular disease, such as ocular trauma, glaucoma, uveitis, diabetic retinopathy, angioid streaks, pathologic myopia, or presumed ocular histoplasmosis syndrome;~2. any systemic contraindication to the PDT, IVR, sodium fluorescein, or indocyanine green dyes;~3. any severe uncontrolled systemic disease, such as uncontrolled hypertention, coronary heart disease, liver failure, or kidney failure.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- photodynamic therapy (Type: EXPERIMENTAL): Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
- intravitreal ranibizumab (Type: EXPERIMENTAL): Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
- combination therapy of PDT and IVR (Type: EXPERIMENTAL): Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who undergone STG (billroth I, billroth II, R-Y STG) within 5 years to treat gastric cancer~* Stage of T1-2N0M0~Exclusion Criteria:~* concomitant therapy with astemizole, cisapride, dihydroergotamine, ergotamine, pimozide, or terfenadine, narcotics, alpha-2-adrenergic agonist, TCA, CCB, dopamine agonist, muscarinic cholinergic antagonists, octreotide, exenatide and GLP-1 agonist, phenothiazines~* chemotherapy Hx.~* hypersensitivity to erythromycin or any component of the product~* pregnancy or lactation~* comobidity : DM, AIDS, neurologic disease(parkinsonism, multiple sclerosis, brainstem stroke or tumor, diabetic or amyloid neuropathy, or primary dysautonomias) scleroderma and other connective tissue disease, recent viral enteritis history~* recurrence

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- erythromycin (Type: EXPERIMENTAL): None
- saline (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has active acromegaly defined as elevated GH and IGF-1 levels (measured at a central laboratory) as outlined below:~  * A serum level for IGF-1 ≥1.3 x upper limit of normal range (ULN) during the screening period (applicable to both treatment naïve subjects and subjects who have stopped treatment and undergone a washout period prior to Visit 1(Week -4).~ * Subjects must have mean serum GH concentration ≥2.5 μg/L in a GH cycle (5 samples taken at 0, 30, 60, 90 and 120 minutes) during the screening period.~* The subject has undergone surgical removal of an adenoma for acromegaly at least 3 months prior to Screening, or is likely to require pituitary surgery in the future but not before completing at least 32 weeks of study treatment plus an additional follow up of 8 weeks for subjects taking part in the pharmacokinetics (PK) extension, or for whom pituitary surgery is not an option (due to contraindications, refusal etc.) and is therefore never likely to undergo pituitary surgery.~Exclusion Criteria:~* The subject has been treated with radiotherapy within 10 years prior to Screening.~* The subject has been treated with lanreotide Autogel, lanreotide PR, pegvisomant, cabergoline or octreotide LAR within 3 months of Screening or octreotide immediate release (IR) or bromocriptin within 2 weeks of Screening.~* The subject has a history of or currently presents with clinically significant ventricular or atrial dysrhythmias ≥Grade 2, using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0.~* The subject has uncontrolled diabetes (glycosylated haemoglobin (HbA1c) \>8.5%).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lanreotide Autogel® 60mg, 90mg and 120mg (Type: EXPERIMENTAL): Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
- Lanreotide 40mg PR (Lanreotide Acetate for Injection ) (Type: ACTIVE_COMPARATOR): Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011~Exclusion Criteria:~* None. Available data from all eligible patients for each center, will be included

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PPI And Food Effect Study For PF-06463922 In Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female subjects of non-childbearing potential and/or male subjects~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).~* Evidence of a personally signed and dated informed consent document.~* Subject must be willing to avoid direct sunlight exposure or any high intensity ultraviolet light exposure~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular~* Any condition possibly affecting drug absorption~* A positive urine drug screen.~* Use of tobacco- or nicotine containing products within 90 days of screening or a positive urine cotinine test and history of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males within 6 months of Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- PF-06463922 (Type: EXPERIMENTAL): each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hemophilia A, any severity, with documented history of high-titer inhibitor (\>5BU); current use of bypassing agents (PCCs, aPCCs or rFVIIa) for treatment of bleeds; \>/= 6 bleeds requiring bypassing therapy in the previous 6 months~Exclusion Criteria:~* concomitant immune tolerance therapy; clinically symptomatic liver disease, platelet count less than 100,000

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On-demand first (Type: OTHER): Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
- Prophylaxis first (Type: OTHER): Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD~* 10 pack-year or greater history of cigarette smoking~* Post-bronchodilator FEV1/FVC of \<0.7~* Predicted FEV1 of 70% of normal or less~* Modified Medical Research Council (mMRC) dyspnea score of 2 or greater~Exclusion Criteria:~* Women who are pregnant, lactating, or planning to become pregnant~* Respiratory disorders other than COPD, including a current diagnosis of asthma~* Clinically significant non-respiratory diseases or abnormalities that are not adequately controlled~* Significant allergy or hypersensitivity to anticholinergics, beta2-agonists, or the excipients of magnesium stereate or lactose used in the inhaler delivery device~* Hospitalization for COPD or pneumonia within 12 weeks prior to screening~* Lung volume reduction surgery within 12 weeks prior to screening~* Abnormal and clinically significant ECG findings at screening~* Clinically significant laboratory findings at screening~* Use of systemic corticosteroids, antibiotics for respiratory tract infections, strong cytochrome P450 3A4 inhibitors, high dose inhaled steroids (\>1000mcg fluticasone propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled beta2-agonists, ipratropium, inhaled sodium cromoglycate or nedocromil sodium, or investigational medicines for defined time periods prior to the screening visit~* Use of long-term oxygen therapy (12 hours or greater per day)~* Regular use of nebulized treatment with short-acting bronchodilators~* Participation in the acute phase of a pulmonary rehabilitation program~* A know or suspected history of alcohol or drug abuse~* Affiliation with the investigational site~* Previous use of GSK573719 or GW642444 alone or in combination, including the combination of fluticasone furoate and GW642444

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719/GW642444 (Type: EXPERIMENTAL): 125/25mcg
- GSK573719 (Type: EXPERIMENTAL): 125mcg
- GW642444 (Type: EXPERIMENTAL): 25mcg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy~* Postmenopausal~* Hysterectomized or non-hysterectomized~* Moderate or severe vaginal dryness and soreness~* Successful completion of the study VAG/PD/009/USA~Exclusion Criteria:~* Known, suspected, or past history of breast cancer~* Known, suspected, or past history of hormone-dependent tumor~* Genital bleeding of unknown etiology~* Acute thrombophlebitis or thromboembolic disorders or a past history of these conditions, associated with previous estrogen use~* Subjects who had adverse events during the final visit, or discontinued prematurely, or were noncompliant in VAG/PD/009/USA~* Exposure to any investigational new drug (other than what was dispensed in VAG/PD/009/USA) within the previous 30 days

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed novel influenza A(H1N1) case with laboratory evidence~* 70 years ≥ age ≥ 14years~* Within 72hr after the onset of symptoms(body temperature≥37.5℃ with at least one respiratory symptom (cough, sore throat, or nasal symptom)~Exclusion Criteria:~* Age \< 14 years or \> 70 years~* Bronchitis, pneumonia, pleural fluid and interstitial infiltration showed by Chest radiology(x-ray or CT)~* Severe chronic underlying diseases: severe COPD(FEV1/EVC \<70% and FEV1 \<30% predicted or respiratory failure or congestive heart failure), severe hepatic disfunction（ALT or AST ≥3 times normal elevation), renal disfunction（Cr\>2mg/dL), chronic heart failure(NYHA Ⅲ-Ⅳ grade）~* Immunocompromised patients(cancer, organ transplant, AIDS and a history of treatment with immunosuppressive drug and glucocorticoids in the past 3 months)~* Taken Chinese medicinal herbs, antiviral or antibiotic drug in the past 2 weeks~* Inoculation influenza vaccination~* One of the following items appeared at the enrollment~  * respiratory failure：PaO2\<60mmHg and/or PCO2\>50mmHg or PaO2/FiO2≤300~ * circulation failure: despite adequate fluid resuscitation and cardiac output, systolic \<90mmHg or requirement inotropic support~ * renal function failure: despite adequate fluid resuscitation and cardiac output, urine ≤ 0.5ml/kg.h, Cr or BUN≥1 time normal elevation~ * hepatic function failure: total bilirubin\>34μmol/L or ALT/AST ≥3 times normal - Other unappropriated enrollment situations considered by investigator

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- blank (Type: EXPERIMENTAL): do not take antiviral therapy
- Oseltamivir (Type: EXPERIMENTAL): antiviral therapy
- chinese medicinary herbs (Type: EXPERIMENTAL): antiviral therapy
- oseltalmivir and chinese medicinal herbs (Type: EXPERIMENTAL): combination antiviral therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VANOS Cream and Skin Barrier Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AD according to Hanifin-Rajka criteria (see Appendix B)~* Age 12 years or older~* Must have an Investigator's Global Assessment (IGA) Score of Moderate, Severe, or Very Severe (See Appendix C)~* Must have failed to achieve adequate disease despite adequate topical or systemic therapy~* Must be a candidate, according to the principal investigator and standard of care, for a super-potent topical steroid course. Subjects that are candidates for super-potent topical steroids are defined as subjects whose disease is not adequately controlled with medium-potency topical steroids or systemic therapy, including phototherapy.~Exclusion Criteria:~* Active skin infection~* Hypersensitivity to any ingredients in Vanos cream~* Previous use of super-potent topical steroids within 2 weeks of starting study (Class I steroid).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vanos Cream (Type: EXPERIMENTAL): glucocorticoid cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) between 18 and 32 kg/m\^2~* In good health, determined be no clinically significant findings from medical history, physical examination, and screening evaluations~* Female subjects must be of nonchildbearing potential~* Male subjects must agree to use contraception or must be surgically sterile for at least 90 days prior to enrollment~* Able to understand and sign informed consent form~Exclusion Criteria:~* Any condition affecting drug absorption (including stomach or intestinal surgery)~* Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder~* History of hypersensitivity, intolerance, or allergy to any drug compounds, food, or other substance (unless approved by Investigator)~* Participation in a clinical study involving an investigational drug within the past 30 days~* Use or intend to any prescription medications within 28 days prior to check in~* Use of tobacco- or nicotine-containing products within 28 days prior to check in~* History of hyperbilirubinemia~* History of alcoholism or drug abuse within 2 years~* History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects~* Positive hepatitis panel and/or positive human immunodeficiency virus (HIV) test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Part A (Type: EXPERIMENTAL): Tucatinib plus Itraconazole
- Part B (Type: EXPERIMENTAL): Tucatinib plus Rifampin
- Part C (Type: EXPERIMENTAL): Tucatinib plus Gemfibrozil
- Part D (Type: EXPERIMENTAL): Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
- Part E (Type: EXPERIMENTAL): Tucatinib plus Digoxin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject diagnosed as having Parkinson's disease in accordance with Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)~2. Subject is 30 years \< \> 80 years at the time of informed consent~3. Hoehn \& Yahr stage 1- 3~4. Total of each sum score of UPDRS Part 2 and 3 is over 10 at screening test~Exclusion Criteria:~1. Subject has previously participated in a trial with SPM 962~2. Subject is on L-dopa treatment for total of over 6 months at the time of informed consent~3. Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test and baseline~4. Subject has orthostatic hypotension~5. Subject has a history of epilepsy, convulsion and other~6. Subject has a complication of serious cardiac disorder/arrhythmia or has the history~7. Subject has arrhythmia and treated with class 1a anti-arrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 anti-arrhythmic drugs (e.g. amiodarone, sotalol etc.)~8. Subject has serious ECG abnormal at screening i.e.; 1) Subject has more than 450 msec of QTc values both in two measurements at screening test 2) Subject has more than 470 msec for females and more than 450 msec for males of mean QTc values of two measurements at baseline~9. Subject has congenital long QT syndrome~10. Subject has serum potassium of less than 3.5 mEq/L at screening test.~11. Subject has total bilirubin of 3.0 mg/dL and above or AST(GOT), ALT(GPT) greater than 2.5 times (or 100 IU/L and above) of the clinical laboratory's upper limit of the reference range at screening test~12. Subject has 30 mg/dL and above of BUN or 2.0 mg/dL and above of serum creatinine at screening test~13. Subject has a history of allergy to topical medicine, e.g. transdermal patch~14. Subject is pregnant, nursing, or is child bearing potential while the trial~15. Subject is receiving therapy with prohibited drug specified in the study protocol~16. Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant~17. Subject has dementia~18. Subject is unable to give consent~19. Subject is participating in another trial of an investigational drug or done so within 12 weeks prior to the initial treatment~20. Investigator judges that subject is inappropriate as a study subject with other reasons

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete